Drag a card by its title · ⚙ to size, swap or remove

The company

Amylyx Pharmaceuticals, Inc.

AMLX · Nasdaq

Health CareBiotechnologyLeadingGLP-1

AMLX stood above a rising 150-day average in 48 of the last 52 weekly readings, including each of the last 18 weeks. It is 25.4% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Leading
Weeks in an uptrend: 18 in a row
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $204K
Insider sales, 12 months: $19.3M
Officials’ trades on record: 1
Institutions holding: 200 (+35)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 48 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

1 disclosed lines: House 1, Senate 0, executive 0; 1 people.

Who	Did	Amount	Traded
Chris Jacobs House: U.S. House ClerkNY27	bought	$1k–$15k	12 Oct 2022filed 16 Nov 2022

Insiders

Buy orders, 12 months2

Sale orders, 12 months26

Buyers · sellers1 · 6

Who	Did	Shares	Traded
George M. Milne, Jr.Director	sold	30,000at $27.70	5 Oct 2026filed 7 Oct 2026
Justin B. KleeCo-Chief Executive Officer	sold	29,025at $32.13	10 Sep 2026filed 14 Sep 2026
Justin B. KleeCo-Chief Executive Officer	sold	1,439at $33.16	10 Sep 2026filed 14 Sep 2026
Joshua B. CohenCo-Chief Executive Officer	sold	29,545at $32.16	10 Sep 2026filed 14 Sep 2026
Joshua B. CohenCo-Chief Executive Officer	sold	919at $33.15	10 Sep 2026filed 14 Sep 2026
Gina MazzarielloChief Legal Officer	sold	9,525at $32.46	10 Sep 2026filed 14 Sep 2026
Gina MazzarielloChief Legal Officer	sold	11at $33.34	10 Sep 2026filed 14 Sep 2026
James M. FratesChief Financial Officer	sold	9,768at $32.27	10 Sep 2026filed 14 Sep 2026
James M. FratesChief Financial Officer	sold	1,042at $33.23	10 Sep 2026filed 14 Sep 2026
Camille L. BedrosianChief Medical Officer	sold	7,947at $32.21	10 Sep 2026filed 14 Sep 2026
Camille L. BedrosianChief Medical Officer	sold	2,081at $33.09	10 Sep 2026filed 14 Sep 2026
Gina MazzarielloChief Legal Officer	sold	15,000at $17.61	10 Jul 2026filed 13 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders200+35 on the quarter

New · exited50 · 15

Reported value$2.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
FMR LLCadded · filed 13 Aug 2026	16,727,909$300.4M	+97,368+0.6%
BlackRock, Inc.reduced · filed 7 Aug 2026	8,827,085$158.5M	-1,7510.0%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 2026	8,334,882$149.7M	+50,000+0.6%
TCG Crossover Management, LLCunchanged · filed 14 Aug 2026	6,243,812$112.1M	00.0%
Commodore Capital LPunchanged · filed 14 Aug 2026	5,650,000$101.5M	00.0%
Jupiter Topco LLCnew · filed 14 Aug 2026	5,236,102$94.0M	+5,236,102
Saturn V Capital Management LPadded · filed 14 Aug 2026	4,624,101$83.0M	+274,216+6.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	4,224,224$75.9M	+82,649+2.0%
MORGAN STANLEYadded · filed 13 Aug 2026	3,130,808$56.2M	+955,261+43.9%
Driehaus Capital Management LLCadded · filed 14 Aug 2026	3,036,970$54.5M	+49,823+1.7%